To investigate whether FH has an impact on the therapeutic efficacy of CRC, we collected samples from 12 patients with rectal cancers treated with neoadjuvant chemoradiotherapy combined with PD-1 antibodies, of which six were treatment-sensitive (tumor reduction of more than 40%) and 6 were treatment-insensitive (tumor reduction of less than 40%). This evidence concerns the gene PDCD1 and rectal cancer.